Stirm K, Leary P, W xfc st D, Stark D, Joller N, Karakus U, et al. Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models. J Immunother Cancer. 2023;11: pubmed publisher

Yoshinaga M, Han K, Morgens D, Horii T, Kobayashi R, Tsuruyama T, et al. The N6-methyladenosine methyltransferase METTL16 enables erythropoiesis through safeguarding genome integrity. Nat Commun. 2022;13:6435 pubmed publisher

Xu L, Tian D, Zhou M, Ma J, Sun G, Jin H, et al. OX40 Expression in Eosinophils Aggravates OVA-Induced Eosinophilic Gastroenteritis. Front Immunol. 2022;13:841141 pubmed publisher

Fernandes H, Zonnari A, Abreu R, Aday S, Bar xe3 o M, Albino I, et al. Extracellular vesicles enriched with an endothelial cell pro-survival microRNA affects skin tissue regeneration. Mol Ther Nucleic Acids. 2022;28:307-327 pubmed publisher

Lin Y, Schmidt M, Sharif G, Vietsch E, Kiliti A, Barefoot M, et al. Impaired CXCL12 signaling contributes to resistance of pancreatic cancer subpopulations to T cell-mediated cytotoxicity. Oncoimmunology. 2022;11:2027136 pubmed publisher

Yang R, Zhou S, Zhou Q. In vitro naphthylquinoxaline thymidine conjugate and UVA treated cancer cells are effective therapeutic vaccines for tumors in vivo with CpG as the adjuvant. J Adv Res. 2022;35:259-266 pubmed publisher

Mo Y, To K, Zhou R, Liu L, Cao T, Huang H, et al. Mitochondrial Dysfunction Associates With Acute T Lymphocytopenia and Impaired Functionality in COVID-19 Patients. Front Immunol. 2021;12:799896 pubmed publisher

Carlet M, Völse K, Vergalli J, Becker M, Herold T, Arner A, et al. In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets. Nat Commun. 2021;12:5655 pubmed publisher

Carpio M, Means R, Brill A, Sainz A, Ehrlich B, Katz S. BOK controls apoptosis by Ca2+ transfer through ER-mitochondrial contact sites. Cell Rep. 2021;34:108827 pubmed publisher

Si J, Shi X, Sun S, Zou B, Li Y, An D, et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer Cell. 2020;38:551-566.e11 pubmed publisher

Evgin L, Huff A, Wongthida P, Thompson J, Kottke T, Tonne J, et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nat Commun. 2020;11:3187 pubmed publisher